NEW YORK – Newly launched PercayAI said today that it entered into a strategic partnership with Canopy Biosciences to bring augmented intelligence to Canopy's multi-omic and gene expression testing.
PercayAI, which introduced its CompBio product this week, will interface its new technology with Canopy Biosciences' RNA sequencing and NanoString diagnostic tests. CompBio applies artificial intelligence and contextual language processing to help researchers identify relationships within multi-omic datasets to inform drug discovery.
"Our collaboration with PercayAI will create a powerful union of genomics expertise with cutting-edge analysis solutions to best support scientists in drug development and lead to better patient outcomes," Canopy Biosciences CEO Edward Weinstein said in a statement.
"With CompBio, researchers can explore the biological landscape and rapidly uncover insights in ways not possible with other tools," added PercayAI Chief Commercial Officer Preston Keller said in a statement. "Through our partnership with Canopy Biosciences, scientists will now have access to a powerful and innovative technological service that will help to improve the speed, cost, and success rate of diagnostic and drug development."
PercayAI, spun out of the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine in St. Louis, and funded by investment firm Kingdom Capital, launched Monday. Canopy Biosciences is also based in St. Louis.